Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric Lymphoma Clear all
Completed Not applicable Interventional

Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment

NCT04400071
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Pediatric Cancer
Interventions
Active Music Engagement, Audio Storybooks
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
3 Years to 8 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Oakland, California • Chicago, Illinois • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Jul 22, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Tipifarnib in Treating Young Patients With Refractory Leukemia

NCT00022451
View directory record Official record
Conditions
Leukemia
Interventions
tipifarnib
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
56
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jul 22, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia

NCT00083070
View directory record Official record
Conditions
Leukemia
Interventions
temozolomide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
14
States / cities
Stanford, California • Indianapolis, Indiana • Minneapolis, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Jul 22, 2026, 5:58 AM EDT
Recruiting Not applicable Interventional

Umbilical Vessel Catheterization Under ECG Monitoring and Guidance

NCT03898596
View directory record Official record
Conditions
Pediatric ALL
Interventions
ECG
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
1 Day to 45 Days
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Jul 22, 2026, 5:58 AM EDT
Completed Phase 1 Interventional Results available

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas

NCT02171260
View directory record Official record
Conditions
Pediatrics, Solid Tumors
Interventions
Eribulin Mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Jul 22, 2026, 5:58 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Acute Concussion and Melatonin

NCT04731974
View directory record Official record
Conditions
Concussion, Mild, Concussion, Brain, Pediatric ALL
Interventions
Melatonin 3 MG, Placebo
Drug · Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
12 Years to 18 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Jul 22, 2026, 5:58 AM EDT
Completed Not applicable Interventional

Robot Rehab: AAI With Robot During Inpatient Pediatric Rehab

NCT05275543
View directory record Official record
Conditions
Pediatric ALL, Child, Hospitalized, Physical Therapy Modalities, Occupational Therapy, Animal Assisted Therapy
Interventions
Paro Robot
Device
Lead sponsor
University of Nebraska
Other
Eligibility
5 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 22, 2026, 5:58 AM EDT
Withdrawn Phase 2 Interventional

Denileukine Diftitox for Relapsed ALCL

NCT00801918
View directory record Official record
Conditions
Anaplastic Large-Cell Lymphoma
Interventions
Denileukin Diftitox, Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide
Drug
Lead sponsor
Columbia University
Other
Eligibility
2 Years to 24 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Jul 22, 2026, 5:58 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

NCT05071209
View directory record Official record
Conditions
Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Alveolar Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
Interventions
Elimusertib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 30 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 22, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

NCT01582932
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene 0.005% Foam
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
2 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Rogers, Arkansas • Encino, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Jul 22, 2026, 5:58 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

NCT03458728
View directory record Official record
Conditions
Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma
Interventions
Copanlisib (BAY806946)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Birmingham, Alabama • Orange, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Jul 22, 2026, 5:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing Neurophysiological and Cognitive Function in School Children

NCT06209528
View directory record Official record
Conditions
Pediatric ALL
Interventions
Not listed
Lead sponsor
Life University
Other
Eligibility
5 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Chippewa Falls, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Jul 22, 2026, 5:58 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States

NCT04928599
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Electronic Health Record Review, Interview, Survey Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
39
States / cities
Oakland, California • Wilmington, Delaware • Fort Lauderdale, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 5:58 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma

NCT04571138
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
SCRI-CAR22v2
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
4
States / cities
Los Angeles, California • Indianapolis, Indiana • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jul 22, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Medication Errors and Adverse Drug Events (ADEs) in Ambulatory Pediatrics

NCT00229671
View directory record Official record
Conditions
Pediatric ALL
Interventions
Survey 1, Survey 2
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Day to 21 Years
Enrollment
6,341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 22, 2026, 5:58 AM EDT
Completed Phase 1Phase 2 Interventional

Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia

NCT01842672
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma/Leukemia
Interventions
Clofarabine, Mitoxantrone
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Up to 30 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Valhalla, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Jul 22, 2026, 5:58 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

NCT02932280
View directory record Official record
Conditions
Solid Tumor, Central Nervous System Tumor, Lymphoma, Leukemia
Interventions
Neratinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 22, 2026, 5:58 AM EDT
Completed No phase listed Observational

Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology

NCT02847130
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Childhood Acute Myeloid Leukemia, Childhood Burkitt Lymphoma, Childhood Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions
Informational Intervention, Interview, Medical Chart Review, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
31
States / cities
Oakland, California • Wilmington, Delaware • Fort Myers, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Jul 22, 2026, 5:58 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL

NCT05215405
View directory record Official record
Conditions
Relapsed Childhood ALL, Relapsed Childhood Lymphoblastic Lymphoma
Interventions
Venetoclax, Navitoclax
Drug
Lead sponsor
Kathleen Ludwig
Other
Eligibility
4 Years and older
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 22, 2026, 5:58 AM EDT
Recruiting Not applicable Interventional

Multiphase Optimization Strategy (MOST) for Treating Pediatric Post-traumatic Stress Disorder (PTSD)

NCT06956781
View directory record Official record
Conditions
PTSD, Trauma, Pediatric ALL
Interventions
Emotion Regulation, Exposure, Cognitive Processing, Bi-lateral Stimulation, Psychological Placebo
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
8 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 22, 2026, 5:58 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

NCT03573700
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory
Interventions
Cyclophosphamide, Fludarabine, Mesna, CliniMACS, CD19- specific CAR engineered autologous T-cells (SJCAR19 product)
Drug · Device · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 22, 2026, 5:58 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

NCT07134088
View directory record Official record
Conditions
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Interventions
Blinatumomab
Drug
Lead sponsor
Amgen
Industry
Eligibility
28 Days to 4383 Days
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Palo Alto, California • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 22, 2026, 5:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01780662
View directory record Official record
Conditions
Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Refractory Childhood Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Months to 30 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
109
States / cities
Birmingham, Alabama • Phoenix, Arizona • Downey, California + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jul 22, 2026, 5:58 AM EDT
Completed No phase listed Observational

Dietary Impact on Continuous Glucose Monitoring

NCT05845827
View directory record Official record
Conditions
Glucose Metabolism Disorders, Dietary Habits, Pediatric ALL, Adult ALL
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
14 Years to 22 Years
Enrollment
30 participants
Timeline
2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Jul 22, 2026, 5:58 AM EDT